Altria stock has busted out of a five-year slump.Tortoise-like tobacco giant Altria Group (MO -0.45%) has been uncharacteristically hot this year. Shares are up over 15% in 2024, an uncommon surge given the stock's poor share price performance over the past five years.The reason for the stock's run? It could be that Altria put its disastrous Juul investment in the rearview mirror, giving investors a chance to focus on what's still a very resilient core business that revolves around its blue chip smokeable b ...

Loading...Loading...Altria Group, Inc. MO shares closed slightly higher during Friday's session.On May 16, the company's board declared a regular quarterly dividend of 98 cents per share, payable on July 10, to shareholders of record as of June 14.On April 25, Altria Group reported a first-quarter FY24 sales decline of 2.5% year-over-year to $5.58 billion. It beat the analyst consensus estimate of $4.71 billion.With the recent buzz around Altria Group, some investors may be eyeing potential gains from the c ...

Core Insights - The FDA has rescinded the marketing denial orders (MDOs) for Juul e-cigarettes, allowing the company a second chance in the review process due to new legal precedents and additional information provided by Juul [1][2] Group 1: Regulatory Developments - The FDA initially issued MDOs to Juul in June 2022, but the ban was put on hold in July 2022 for further review of scientific issues [1] - The FDA's review includes toxicology, engineering, social science, and clinical pharmacology [1] - The rescission of the MDOs does not indicate whether the applications will ultimately be authorized or denied [1] Group 2: Product and Health Concerns - Juul manufactures e-cigarettes and e-liquid pods that vaporize nicotine salts for inhalation [2] - The FDA has raised concerns about Juul's marketing strategies, particularly their appeal to teenagers and claims of being safer than traditional cigarettes [2] - There are potential health risks associated with chemicals in Juul's e-liquid, such as benzoic acid, which can be hazardous in large amounts [2]

Altria is a longtime dividend powerhouse.Tobacco stocks have long been popular among income investors. Few industries have had the same luxury of selling a recession-proof product at wide profit margins, which has allowed tobacco companies to return much of their profits to investors in the form of dividends.Altria (MO 0.02%) certainly fits the bill here, and the stock had an incredible run of almost 50 years. Through 2014, it delivered an average annual total return of 20.6%, according to Wharton professor ...

These stocks all yield more than 6%.Dividend stocks help you to make money with no effort on your part. And that passive income can be incredibly powerful if it's reinvested long-term and piles up over the years. It's also a big part of why high-yielding dividend stocks can be particularly enticing, as they provide investors with more bang for their investment bucks.But high yields also tend to come with increased risk. Three of the highest-yielding dividend payers among stocks in the S&P 500 today are Walg ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

ToplineThe Food and Drug Administration rescinded its marketing ban on Juul Lab’s e-cigarette products Thursday—placing them back under scientific review—nearly two years after ordering a ban that was halted pending the company’s appeal.The FDA issued the ban of the popular e-cigarettes in June 2022. Getty Images Key FactsThe agency rescinded its marketing denial orders for the e-cigarette maker’s products after further review of information provided by Juul—as well as new case law. Juul Lab’s products hav ...

Altria NYSE: MO is among the leading sin stocks but is still a good dividend play today. Up more than 17.5% in the last few weeks, the purveyor of tobacco products is on track to reclaim the high end of a long-term trading range and possibly set new highs. Among the drivers for this move is the company’s considerable cash flow, which is used to repurchase shares, pay market-beating dividends, and maintain a healthy balance sheet. Get Altria Group alerts:Here are 7 Compelling Reasons Altria is A Good Buy for ...

Altria (MO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this owner of Philip Morris USA, the nation's largest cigarette maker have returned +3%, compared to the Zacks S&P 500 composite's +3.2% change. During this period, the Zacks Tobacco industry, which Altria falls in, has gained 3.3%. The key question now is: What could be the stock's future direct ...

Group 1: Company Overview - Altria is a consumer products maker with a leading position in the cigarette industry, particularly with its Marlboro brand, which holds 42% of the U.S. cigarette market [2] - The company has a significant 8.5% dividend yield, which could generate substantial cash for investors [1][3] - Despite the high dividend yield, Altria's stock is down approximately 40% from its 2017 highs, indicating potential recovery opportunities [3] Group 2: Industry Challenges - The cigarette industry is facing long-term decline, with Altria producing 10% fewer cigarettes in Q1 2024 compared to the same period in 2023 [2] - Price increases have helped offset declines in cigarette production, but this may not be a sustainable long-term strategy [4] Group 3: Management Strategies - Altria has attempted to diversify its business by investing in vaping and marijuana companies, but these investments have resulted in significant write-offs [5] - The recent acquisition of NJOY, a vaping company, shows promise as it is further along in development compared to previous investments [6] - Management needs to effectively utilize cash generated from its cigarette business to build new growth avenues to ensure long-term viability [4][7] Group 4: Investment Considerations - Investing in Altria carries risks due to its reliance on a declining cash cow business, and past efforts to diversify have not been successful [7] - The potential for NJOY to be a turning point for Altria's business could make it an attractive investment, but this remains uncertain [6][7]